Sai Life Sciences Limited (NSE:SAILIFE)
India · Delayed Price · Currency is INR | Market Cap | 309.14B +62.5% |
| Revenue (ttm) | 22.50B +17.7% |
| Net Income | 3.62B +48.2% |
| EPS | 17.02 +43.2% |
| Shares Out | 212.12M |
| PE Ratio | 85.62 |
| Forward PE | 69.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 323,792 |
| Open | 1,483.00 |
| Previous Close | 1,471.60 |
| Day's Range | 1,448.40 - 1,485.00 |
| 52-Week Range | 783.85 - 1,484.20 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 1,552.67 (+6.54%) |
| Earnings Date | Aug 6, 2026 |
About Sai Life Sciences
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India. [Read more]
Financial Performance
In fiscal year 2026, Sai Life Sciences's revenue was 21.92 billion, an increase of 29.38% compared to the previous year's 16.95 billion. Earnings were 3.49 billion, an increase of 105.08%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SAILIFE stock is "Buy." The 12-month stock price target is ₹1,553, which is an increase of 6.54% from the latest price.
News
Sai Life Sciences Transcript: Q1 26/27
Q1 FY 2027 revenue rose 12% YoY, led by strong CRO and CDMO growth, with robust momentum in integrated and FTE-based pharma partnerships. Capacity expansion and new capabilities in peptides and formulations support a 15%-20% mid-term growth outlook.
Sai Life Sciences Quarterly report: Q1 2027
Sai Life Sciences has published its Q1 2027 quarterly earnings report on August 7, 2026.
Sai Life Sciences Slides: Q1 2027
Sai Life Sciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 7, 2026.
Sai Life Sciences Transcript: Q4 25/26
FY 2026 delivered 29% revenue growth, 56% EBITDA growth, and 109% PAT growth, with large pharma now contributing 49% of revenue. CapEx is set to rise to INR 1,100-1,300 crores in FY 2027, focused on capacity and technology, while maintaining 28%-30% EBITDA margins.
Sai Life Sciences Quarterly report: Q4 2026
Sai Life Sciences has published its Q4 2026 quarterly earnings report on May 15, 2026.
Sai Life Sciences Slides: Q4 2026
Sai Life Sciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Sai Life Sciences Transcript: Q3 25/26
Q3 FY 2026 saw 27% revenue and 86% profit growth year-over-year, with strong margin expansion and robust performance in both CDMO and CRO segments. Strategic investments in capacity, technology, and portfolio diversification support sustained growth and margin guidance of 28%-30%.
Sai Life Sciences Quarterly report: Q3 2026
Sai Life Sciences has published its Q3 2026 quarterly earnings report on February 6, 2026.
Sai Life Sciences Slides: Q3 2026
Sai Life Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 6, 2026.
Sai Life Sciences Transcript: Q2 25/26
Q2 FY26 saw strong revenue and EBITDA growth, driven by robust CDMO and CRO performance, operational efficiencies, and strategic investments in new modalities and capacity. The company remains confident in achieving 15%-20% revenue growth over the next 3-5 years, with a diversified portfolio mitigating product concentration risks.
Sai Life Sciences Quarterly report: Q2 2026
Sai Life Sciences has published its Q2 2026 quarterly earnings report on November 7, 2025.
Sai Life Sciences Slides: Q2 2026
Sai Life Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 7, 2025.